Lancet study of severe outcomes amongst 30 million Brits finds that if you exclude deaths and adverse events within 14 days - you should get more injections

From here:

Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales - The Lancet

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01656-7/fulltext

We have this little nugget:

“We excluded events that occurred within the first 14 days after completion of the primary vaccination schedule to allow time for a full immune response to be mounted. For the same reason, the 14-day period after a booster dose was counted as the exposure period after the primary vaccine dose.”

How many deaths might have occurred within that 14 day period? Well, the US VAERS provides a clue for these “spontaneous” deaths.

Eye-balling that bar-chart, maybe 90% of deaths reported to VAERS occur within 14 days. Presumably, hospitalizations that arise within the 14 day period that persist beyond 14 days are included, but those resolved within 14 days are not.

Given that the study used data from ..”four near real-time nationwide health-care datasets stored in separate secure Trusted Research Environments (TREs) in England, Northern Ireland, Scotland, and Wales. “ - there is a ZERO under-reporting factor (beyond ignoring the two weeks when most deaths and adverse events occur). Any sampling errors are strictly limited by the statistical techniques used.

The findings of the report are here:

“Between Dec 8, 2020, and Feb 28, 2022, 16 208 600 individuals completed their primary vaccine schedule and 13 836 390 individuals received a booster dose.

Between Dec 20, 2021, and Feb 28, 2022, 59 510 (0·4%) of the primary vaccine group and 26 100 (0·2%) of those who received their booster had severe COVID-19 outcomes.

The risk of severe COVID-19 outcomes reduced after receiving the booster (rate change: 8·8 events per 1000 person-years to 7·6 events per 1000 person-years). (Ed: so less than one in a thousand).

Older adults (≥80 years vs 18–49 years; aRR 3·60 [95% CI 3·45–3·75]), those with comorbidities (≥5 comorbidities vs none; 9·51 [9·07–9·97]), being male (male vs female; 1·23 [1·20–1·26]), and those with certain underlying health conditions—in particular, individuals receiving immunosuppressants (yes vs no; 5·80 [5·53–6·09])—and those with chronic kidney disease (stage 5 vs no; 3·71 [2·90–4·74]) remained at high risk despite the initial booster (Ed: so no benefit from a booster).

Individuals with a history of COVID-19 infection were at reduced risk (infected ≥9 months before booster dose vs no previous infection; aRR 0·41 [95% CI 0·29–0·58]). (Ed: natural immunity is better for protecting from infection).”

Those wanting a refresher on absolute risk reduction (aRR) and other statistical measures can check this out:

Relative risk, relative and absolute risk reduction, number needed to treat and confidence intervals - Smart Health Choices - NCBI Bookshelf (nih.gov)

https://www.ncbi.nlm.nih.gov/books/NBK63647/

The Lancet has this interpretation of its findings:

“Older people, those with multimorbidity, and those with specific underlying health conditions remain at increased risk of COVID-19 hospitalisation and death after the initial vaccine booster and should, therefore, be prioritised for additional boosters, including novel optimised versions, and the increasing array of COVID-19 therapeutics.”

So there you have it. If you ignore all deaths and adverse events tht occur within 14 days of either the Pfizer/BioNTech mRNA or Astra Zeneca viral vector C19 injections, (where the vast majority of deaths and “adverse events” occur, you should get boosted.

Out of interest, I repost this table extracted from the European vaccine adverse event reporting system, EUDRA and reported in my article here.

C19 Injection global death toll - somewhere between 9 million and 45 million. Injuries somewhere between 840 million and 4.2 billion (multiple injuries per person) (substack.com)

https://peterhalligan.substack.com/p/c19-injection-global-death-toll-somewhere

“Other “vaccines” did not have much significance compared to these top 4 manufacturers.

Astra Zeneca and JnJ are both viral vector “vaccines”. Compared to Pfizer, they are 4-5 times more deadly than the already deadly Pfizer BioNTech mRNA injection. The same 4-5 times worse ratio applies to Astra Zeneca against Moderna and PfizerBioNTech for adverse events.”

There is no mention of the relative dangers between mRNA and viral vector injections. The distribution of doses by manufacturer in the UK is not available on the OurWorldinData website.

Information of UK C19 injections is here:

England Summary | Coronavirus (COVID-19) in the UK (data.gov.uk)

https://coronavirus.data.gov.uk

• Last 7 days – first dose 7,686

• Total – first dose 45,351,924 = 94%

• Last 7 days – second dose 13,600

• Total – second dose 42,842,246 = 89%

• Last 7 days – booster or third dose 20,826

• Total – booster or third dose 33,804,868 = 70%

So you could say that 6% of the Great Britain (UK -Northern Ireland = Great Britain) is unvaxxed, 11% refused the second dose and 30% the booster.

However, the percentages refer to qualifying population as the numbers and percentages correlate to a population of 48.2 million and not either the UK population of 68.5 million or the population of Great Britain of 2 million in Northern Ireland.

Here is the vaccination schedule for the UK - everyone over 5 years old is eligible for a C19 injection.

NHS vaccinations and when to have them - NHS (www.nhs.uk)

ttps://www.nhs.uk/conditions/vaccinations/nhs-vaccinations-and-when-to-have-them/

I doubt that there have been any short, medium or long term studies of adverse events from these vaccines, in much the same way that no work has been done on C19 injections.